iBio Inc. 公布了一项研究结果,显示在肥胖非人灵长类动物模型中,单次施用候选药物IBIO-610可在长达八周的时间内,实现近乎完全的活性激活素E抑制。该数据揭示了该疗法在靶向这一特定通路方面具有持久的药理活性。
iBio Inc. 公布了一项研究结果,显示在肥胖非人灵长类动物模型中,单次施用候选药物IBIO-610可在长达八周的时间内,实现近乎完全的活性激活素E抑制。该数据揭示了该疗法在靶向这一特定通路方面具有持久的药理活性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.